Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ADH1B | P00325 | 4/20 | 0.43 |
| ▸ | ADH1A | P07327 | 4/20 | 0.43 |
| ▸ | ADH1C | P00326 | 3/20 | 0.40 |
| ▸ | ADH7 | P40394 | 2/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888693 | 0.75 | HTT (0.45) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13708739 | 0.75 | HTT (0.45) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13708740 | 0.75 | HTT (0.45) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL28481257 | 0.74 | HTT (0.44) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25142177 | 0.73 | ALDH1A1 (0.46) | HTTADH1BADH1AADH1CADH4 | |
| SCHEMBL25590015 | 0.71 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25589521 | 0.71 | SMN1; SMN2 (0.46) | HTTSMN1; SMN2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10749845 | 0.69 | ADH1B (0.37) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL17541189 | 0.69 | POLB (0.41) | HTTSMN1; SMN2POLBGAAMAPT | |
| SCHEMBL1463750 | 0.69 | POLB (0.41) | HTTSMN1; SMN2POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| WO-2023078231-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-2881394-B1 | CONDENSED RING HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | HTT 2813/4885ADH1B 1897/4885ADH1A 3415/4885 |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | HTT 2813/4885ADH1B 1897/4885ADH1A 3415/4885 |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | ACE2, ACE, SARS1 | HTT 2813/4885ADH1B 1897/4885ADH1A 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.